ArcherDX Growth, Revenue, Number of Employees and Funding

Overview

Location:
Boulder, CO USA
Total Funding:$95M
Industry:Biotech
Founded:2013
Lead Investor(s):Boulder Ventures, PBM Capital Group, LLC
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • ArcherDX's revenue is currently $36.3M per year.
  • ArcherDX received $35.0M in venture funding in March 2018.
  • ArcherDX's revenue per employee is $227987
  • ArcherDX's total funding is $95M.

Employee Data

  • ArcherDX has 159 Employees.
  • ArcherDX grew their employee count by 43% last year.
  • ArcherDX currently has 32 job openings.

What Is ArcherDX?

ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types. By combining novel enrichment chemistry, automated informatics and a user-friendly workflow, Archer products remove the bottlenecks associated with using next-gen sequencing in a translational setting.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

159

Number of Employees

$36.3M

Revenue (est)

32

Current Jobs

43%

Employee Growth %

$95M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
MBio Diagnostic...
N/A320%
GlobeImmune
N/A330%
Biodesix
$19.1M14620%$182M
miRagen Therape...
$3.9M8019%public
Inscripta
N/A8989%$134.2M
ArcherDX
$36.3M15943%$95M
Clovis Oncology
$95.4M48021%$763.3M
Cerapedics
$10.5M5138%$112.3M

ArcherDX News

15-Feb-19 - ArcherDX Enters Newborn Screening Market with Baby Genes

ArcherDX is expanding its product portfolio with newborn and screening tests to identify carriers of genetic variants linked to different disorders,

5-Mar-19 - ArcherDX Announces Expansion of Executive Leadership Team as

BOULDER, Colo., March 5, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough

14-Feb-19 - ArcherDX announces strategic collaboration with Genosity

ArcherDX, a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalised

ArcherDX Funding

DateAmountRoundLead InvestorsReference
2018-03-21$35.0MABoulder Ventures, Ltd.Article

ArcherDX Acquisitions

DateCompany NameAmountNotesReference
2019-01-31Baby Genes, IncArticle